{"filing":{"accession_number":"0001214659-26-008772","cik":"0001677077","ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"p7202618k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926008772/p7202618k.htm"},"events":[{"id":19180,"run_id":17257,"accession_number":"0001214659-26-008772","anchor_item_number":"8.01","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Dr. Lynne Fahey McGrath, a director since the Company's June 2021 IPO, passed away on July 20, 2026. This constitutes a departure of a director from the Board due to death. The disclosure is material as it affects the composition of the Board and the loss of a long-serving director with significant biopharmaceutical expertise, which would affect a reasonable investor's assessment of the Company's governance and leadership.","company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":18196,"accession_number":"0001214659-26-008772","item_number":"8.01","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Lynne Fahey McGrath, a director since the Company's June 2021 IPO, passed away on July 20, 2026. This constitutes a departure of a director from the Board due to death. The disclosure is material as it affects the composition of the Board and the loss of a long-serving director with significant biopharmaceutical expertise, which would affect a reasonable investor's assessment of the Company's governance and leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:31:54.479527+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18196,"accession_number":"0001214659-26-008772","item_number":"8.01","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Lynne Fahey McGrath, a director since the Company's June 2021 IPO, passed away on July 20, 2026. This constitutes a departure of a director from the Board due to death. The disclosure is material as it affects the composition of the Board and the loss of a long-serving director with significant biopharmaceutical expertise, which would affect a reasonable investor's assessment of the Company's governance and leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:31:54.479527+00:00","company_name":"Alzamend Neuro, Inc.","ticker":"ALZN","filing_date":"2026-07-21"}]}